Bu proje Avrupa Birliği ve Türkiye Cumhuriyeti tarafından finanse edilmektedir
This project is co-funded by the European Union and the Republic of Türkiye

TÜRKİYE in HORIZON 2020
COOPERATION, INNOVATION, COMPETITIVENESS

HOW TO CREATE WINNING SHORT AND FULL PROPOSALS FOR EIC ACCELERATOR

EIC Accelerator – Support for Deep Tech Innovators

Serkan BOLAT

March 11, 2024 – Project Writing Camp 11

Ankara

REPUBLIC OF TÜRKİYE
MINISTRY OF INDUSTRY AND TECHNOLOGY

COMPETITIVE SECTORS PROGRAMME

TÜBİTAK

Serkan BOLAT

SME & EIC Expert

linkedin.com/in/sbolat

Proposal Evaluator & Reviewer

1.000+ proposals 10+ years

170+ EIC Accelerator Short & Full Applications

Consultant & Mentor

Management Marketing Innovation € Investment

25+ Year Work Experience

w/ SMEs, researchers, and founders

Former Navy Supply Officer

PhD Dropout

Retail and Consumer Sciences, M.Sc.

Business, M.A.

Industrial Engineering, B.Sc.

Disclaimer

This presentation with all the data, charts, projections, estimations, and opinion provided within is provided for informational purposes only, and should not be relied upon as proposal submission, legal, business, or investment advice. They may differ from those offered by other individuals, experts, institutions, or authorities. If you refer to this presentation after the indicated event date, its content may be entirely irrelevant. Official EU references, call documents, and program implementation rules may change without prior notice.

The European Commission, the European Innovation Council, the Republic of Türkiye Ministry of Industry and Technology, TÜBİTAK, or any member of Türkiye in Horizon 2020 Phase II Project Consortium as well as their affiliates can not be held responsible for any decisions, actions, or their consequences based on its content.

Although the best effort have been demonstrated to create the most reliable and relevant content, you should always refer to EIC web page and EIC Calls for up-to-date information and legal requirements.

European Innovation Council

PATHFINDER

TRANSITION

ACCELERATOR

BUSINESS ACCELERATION SERVICES

PRIZES

Europe's biggest deep-tech investor

€1 billion approved investments by the EIC Fund in 159 companies since 2022

Backing visionary entrepreneurs

The EIC is Europe's flagship programme to identify, develop and scale up breakthrough technologies and game changing innovations

Leveraging private co-investment

Co-investment leverage of 3 | €43.05 billion combined portfolio valuation

Scaling up innovations

10 EIC-backed unicorns | 112 EIC-backed centaurs | 665 research projects

Fostering woman entrepreneurship

20% funded companies led by women

EIC Accelerator

For details:
EU User Guide to the SME Definition

2024 BUDGET	
Open Call	**6 Challenge Calls**
€375M ~70 projects	**€300M** ~55 projects
€150M Grant	€120M Grant
€225M Equity	€180M Equity

Who is eligible?

Sole SMEs in a Member State or an Associated Country - No consortiums
*One or more **individuals** or legal entities to establish or invest in an SME*

What type of support available?

Grant only and **Blended finance** funding,
*with **Equity-only** restricted to previous grant-only beneficiaries*
Lump sum grant < €2.5M 70% financing for TRL 5-8 & **Investment** < €15M
Business Acceleration Services

Which projects are suitable?

TRL ≥ 5 high-impact market-creating **deep tech** innovations
High risk justifying the need for EIC to crowd in VCs,
EIC to invest <50% of the investment round total
Any topic/industry except military tech ⌛ **~2 year** grant project duration

How to apply?

Submit a **Short Proposal** any time & **Full Proposal** by cut-off dates

EIC Accelerator Challenge Calls - 2024

Human Centric Generative AI made in Europe

- Foundation language and multimodal 'frontier' models
- Smaller foundation models in specific domains

Enabling virtual worlds and augmented interaction to support the realization of Industry 5.0

- AR/VR solutions
- Wearables, smart textiles, and smart objects
- Spatial computing and location mapping

Enabling the smart edge & Emerging quantum technology components

- Novel semiconductor components and integrated smart systems
- Fault-tolerant quantum computing hardware, sensors, communication devices

Food from precision fermentation and algae

- Bacteria, yeast, or fungi-based fermentation systems
- Macro-and micro-algae based novel aquaculture systems

Monoclonal antibody(mAbs)-based therapeutics for new variants of emerging viruses

- Development of broad-spectrum and targeted mAbs-based therapies
- Rapid and simplified testing, production, and administration of mAbs-based therapies

Renewable energy sources (RES) and their whole value chain

- Manufacturing of RES that produce heat and electricity from renewable sources
- Technologies for exploring, mining/processing, synthesizing materials, excluding CRM, that are part of RES
- Technologies for recycling or re-use of RES components

€50M budget for each Challenge Call

Choice specified in Full Application.

No concurrent submission to multiple Calls.

Switching between Open/Challenge Calls permitted.

No obligation to submit to a Challenge call.

Challenge Call topics change annually.

1. Follow your own path. Challenge the status quo.

Is business development allowed in the Accelerator or is e.g. market study etc not adviced (since these things needs to be known beforehand)?

Can you give examples of measures for involving and empowering key actors that have the potential to take the lead in translating research into innovations?

Is a license agreement sufficient for a company to apply, develop and commercialise a technology? Or do you require the company to own the IP (patents)?

What are the conditions to apply for blended, is it necessary to have an investor ready to invest, or would it be ok to start conversations during the project?

2. Aspire beyond the technology



3. Turn your technology into a blessing


Welcome to the United Nations

Artificial Intelligence – a blessing or a curse for sustainable development?

10 November 2023 – In recent years, the use of Artificial Intelligence (AI) has grown rapidly, affecting many industries and areas of human life. But should we view AI as a blessing or curse? How about its impact on social development and the global goals? We spoke with **Professor Daron Acemoglu** of the Department of Economics at the Massachusetts Institute of Technology, who shared his take.


The Economist ≡ Menu Subscribe Log in

Finance & economics | The Golden State's golden egg

Peter Thiel says California suffers from a "tech curse". Is he right?

The state is fabulously rich and fabulously dysfunctional

Technology Curse: *The apparent paradox that a strong technology industry is associated with social dysfunction and declining standards of living rather than prosperity, happiness, and freedom.*

6

European Commission | CORDIS EU research results

HORIZON EUROPE

A novel and accurate emotion recognition system for real-time and continuous patient monitoring in psychiatry

Project Information

ADAPTE

Grant agreement ID: 190129251

DOI

10.3030/190129251

Cephalgo

Grant-first | March 2023 cut-off

European Commission | CORDIS EU research results

HORIZON EUROPE

Optimization, demonstration of natural, biodegradable packaging from wood in desired shapes for various industries

Project Information

RAIKU bio packaging

Grant agreement ID: 101145196

RAIKU®

Blended finance | June 2023 cut-off

European Commission | CORDIS EU research results

HORIZON EUROPE

First automated risk management platform to enable safety, fairness, explainability, and continuous monitoring of generative AI systems

QUANTPI

Grant-only | June 2023 cut-off

We target the global AI market, which has current value of €187.1B (TAM) and a CAGR of 37.3% until 2029. In this TAM, the generative AI market with €12.5B and 27% CAGR constitutes a sub-market addressed by us. AI risk management and governance sector (SAM) has a current market value of €220M and a CAGR of 42.1% until 2029. Industry leaders, e.g. Musk and Wozniak, request a stepping back from training models with an ever-increasing complexity. QuantPi's platform is the first all-in-one, model-agnostic, plug & play solution for risk management of generative AI. For the first time, we enable companies developing or operating generative AI systems to automatically assess and mitigate major risks across dimensions such as performance, fairness, robustness, explainability, and more. Our solution assesses conformance with +100 standards and regulations, including the EU AI Act, ISO/IEC 23894, and NIST AI RMF and assists companies in their pursuit of responsible and trustworthy AI systems.

CORDIS page & quantpi.com

QuantPi

Grant agreement ID: 101144749

DOI

10.3030/101144749

EC signature date

31 January 2024

Start date 1 February 2024

End date 31 January 2026

Funded under

The European Innovation Council (EIC)

Total cost

€ 3 569 250,00

EU contribution

€ 2 498 475,00

Coordinated by

QUANTPI GMBH

Germany

41

Presentations of SME Webinar 17 (Short Application) and SME Webinar 18 (Full Application) are accessible on Help Desk

Winning Projects in Pitch Decks



Pitch Deck examples for EIC Accelerator applications are available on our Help Desk

Winning Projects in Pitch Videos

EIC Pitch Video by QUANDELA *(SME Instrument Phase 1 grantee - 2018)*

SEPOQC "Scalable Entangled-Photon based Optical Quantum Computers" won **blended finance** support at **June 2022** cut-off.

EIC Pitch Video by CRYPTO QUANTIQUE *(SME Instrument Phase 2 grantee - 2020)*

QRYPTON "Quantum secuRe crYptograPhy to secure IoT devices in deep submicrOn Nodes" won **grant-only** support at **March 2023** cut-off.

EIC Pitch Video by INOBIOSTAR *(Women TechEU Winner – 2023)*

InnoAerogel "Sustainable deep tech innovation for aquatic oil spills clean-up" received **Short Proposal** approval in **December 2023**.

EIC Funding Mechanisms - 2024

PATHFINDER		TRANSITION	ACCELERATOR	
TRL 1-4		**TRL 3-6**	**TRL 5-9**	
Open Call	**5 Challenge** Calls	**Open** Call	**Open** Call	**6 Challenge** Calls
€136M ~50 projects	**€120M** ~32 projects	**€94M** ~42 projects	**€375M** ~70 projects	**€300M** ~55 projects
March 7	**October 16**	**September 18**	Full Proposals **March 13**, **October 3** Short Proposals **any time**	
~3-4 years	**~3-5** years	**1-3** years	**2** years	
Grant < **€3M** 100% financing	Grant < **€4M** 100% financing	Grant < **€2.5M** %100 financing	Grant < **€2.5M** 70% financing for TRL 5-8 Investment < **€15M**	
•**Consortiums** of **≥3** (Universities, research organizations, SMEs, industrial partners, or individuals.)	•**Single** universities, SMEs, or research organizations, or •**Consortiums** of **≥2** (SMEs, research organizations, large companies, customer organizations or potential end users (i.e., hospitals, utilities, industry, regulatory and standardization bodies)	•**Single** SMEs, universities, research/technology organizations, teams, individual Principal Investigators, or inventors to establish a spin-off (single large companies ineligible), or •**Consortiums** of **2-5**	•**Single SME**s, individuals to establish an SME, or small midcaps in exceptional cases	

Rule: If consortium of 2, each from a different Member State or Associated Country. If consortium of ≥3, at least from 3 different countries with 1 from a MS.

Deep tech



In 2023, EIC Accelerator funded…

…emotion recognition system… in psychiatry

…cancer diagnostics with Artificial Intelligence

…fault tolerant quantum computers

electrification of heavy machinery

hydrogel biodegradable ureteral stent

…eliminating pesticides

…needle by needle knitting machine

…non-surgical repair for pelvic organ prolapse

…individualized T-Cell immunotherapy for cancer…

…nano coating process… the green hydrogen revolution

…color conversion ink technology for microLED apps

optimization… software for… semiconductor development

personalized lung treatment…through a deeptech AI…

disrupting the cooling and heating… magnetocaloric technology…

Selected Winning AI projects, 2023 (17 out of 172)

Jan	Intelligent Lab on Fiber: **AI-augmented** photonics to identify and quantify disease biomarkers	Ilof
	First modular, interconnected, data- and **AI-driven** software platform for the digitisation of patient care in the healthcare industry	Avelios
Mar	**AI-centric** Server on Chip for increasing complexity and scale of **AI inference** applications, enabling the scale of real-life **AI applications**	Neureality
	First fast and automated (<5 min) **AI-based** inspection to increase operational safety of large critical infrastructure, e.g., bridges, dams, and oil & gas platforms and refineries	Twinsity
	Facilitating personalised Lung Treatment Decisions through a Deeptech **AI** Clinical Decision Support System	Thirona
	Quality Assurance for **AI**	Giskard
	Integrated **AI-based** Clinical Decision Support for Radiologists	Contextflow
	A disruptive hypoxia activated prodrug for treatment of resistant cancers: an **AI-driven** approach	Convertpharma
	Empowering Radiologists in Cancer Diagnostics with **Artificial Intelligence**	Bettermedicine
Jun	A privacy layer to power all research and **AI workflows**	Sarus
	Scalable Unified Processor Enhancing … Computing, Harnessing Integrated Performance for **Edge AI**, Autonomous Driving, **Generative AI**, and Decentralized **AIoT Applications**	Vsora
	First automated risk management platform to enable safety, fairness, explainability, and continuous monitoring of **generative AI systems**	Quantpi
	A novel hardware & software platform to revolutionize **AI** at the edge	Axelera
	An **AI application** for augmented reality glasses to provide intelligent on-demand cueing to assist everyday walking for people with Parkinson's disease anywhere, anytime	Strolll
Nov	A fully autonomous solar-powered lightweight weeding robot, using **AI** for plant recognition, precision contact and contactless weeding methods suited for hard soils…	Smartfarmrobotix
	The first IVDR-approved… software solutions for **AI-powered** RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer	Qlucore
	OMI **AI** ECG Model - application for more accurate heart attack diagnosis	Powerfulmedical

Proposal Submission



1

Create a **personal account**
[EU authentication service]



2

Register as a **company/individual** and receive your **PIC** (Participant Identification Code)
[Participant Register]



3

Select a call to apply for on F&T opportunities portal
[EIC calls]

EIC Accelerator Application Steps and Content

Short Application

- Administrative info PART A (online forms)
- Proposal Form PART B (max. 12 pages)
- Pitch Deck (max. 10 slides)
- Pitch Video (max. 3 min.)
- Consent for data sharing

Funding type and amount in Short Proposal are only indicative.

Full Application

- Administrative info PART A (online forms)
- Proposal Form PART B (max. 50 pages)
- Pitch Deck
- Pitch Video (max. 3 min.)
- Freedom-to-Operate Analysis
- Data Management Plan
- Financial Plan & Equity needed
- Detailed Budget Table for lump sum
- CVs of key personnel
- Letters of Intent
- Annex (optional, max. 10 pages)
- Consent for data sharing

Download
Full Application Forms & Templates

Jury Interview

- Presentation w/ Full Application Pitch Deck (10 minutes)
- Q&A session (35 minutes)

EIC Fund can invest up to €2M above the requested amount; also, follow on within max. €15M limit per beneficiary.

Fast Track & Plug-in schemes to skip Short Proposal stage

Proposals funded by eligible programs/bodies may directly submit to Full Proposal stage

Fast Track: Eligible EU programs/bodies

- EIC Pathfinder, Transition, and Accelerator grant-only beneficiaries
- Selected EIT - Knowledge and Innovation Communities (KICs)
- EUREKA - SME funding schemes under Eurostars-2 Joint Program, and Partnership on Innovative SMEs

Plug-in: EC-certified eligible national and regional public programs/bodies

- List of programs certified for Plug-in scheme

- Eligible funding programs/bodies review the projects against **similar criteria** used for EIC Accelerator **Short Proposal** stage.
- Successful applicants are invited to prepare a Full Proposal within **next 12 months**.
- The rest is **the same**, i.e., business coaching, resubmission limits, and Full Proposal evaluation.

EIC Accelerator Application and Evaluation Process



[1] *Approval of Short Proposals submitted in **2023** only valid for **2024**.*

- Evaluator/Jury pools are **different** for each evaluation step. Evaluators **cannot** access previous submissions/results.
- **3 resubmissions** limit in total at **any stage** for the **same(improved)** proposal from **the same** entity during Horizon Europe. Submissions in **previous** years **do not** count. Concurrent submission/implementation **not** allowed.
- If **investment** decision **not made** during -or **1 year** after- the grant project; then, an **equity-only application** needed.

EIC Accelerator Evaluation Criteria

Excellence

- Excellence of the company
- Novelty and breakthrough character of the innovation
- Timing
- Technological feasibility / TRL
- Intellectual Property Strategy

Impact

- Competitiveness and demand
- Market development
- Commercialization strategy
- Scale up potential.
- Broader impact

Level of risk, implementation, and need for Union support

- Team
- Risk level of the investment
- Risk mitigation
- Implementation plan

Short Proposals are evaluated against **only** the indicated criteria.

Jury Interview step does **not** have evaluation criteria of its own.

All criteria equally apply to both **Open** and **Challenge** Calls, considering the specific **objectives, outcomes, and impact** outlined under each Challenge Call.

EIC Accelerator Full Proposal Remote/Interview Evaluation Criteria

Excellence (1/3)

Excellence of the company: Does the company have a clear mission and vision and partnerships to realize their ambition to scale up?

Novelty and breakthrough character of the innovation: Does the innovation have breakthrough character and a high degree of novelty compared to existing solutions, and *for Challenge Calls, is it addressing the specific objectives of the challenge*?

Timing: Is the timing right for this innovation in terms of users, societal or scientific of technological trends and developments?

Technological feasibility: Has the technology been developed in a safe, secure, and reliable manner? Has it been adequately assessed, validated or certified?

Intellectual Property Strategy: Does your company have the necessary IPR to ensure freedom to operate and adequate protection of the idea?

EIC Accelerator Full Proposal Remote/Interview Evaluation Criteria

Impact (2/3)

Competitiveness and demand: Is the innovation better than what the competition proposes, and is the solution bringing sufficient added value to trigger demand from potential customers?

Market development: Does the innovation have the potential to develop new markets or significantly transform existing ones? Has the potential market for the innovation been adequately quantified, including conditions and growth rates? Is the expected market share acquisition reasonably ambitious and reachable?

Commercialization strategy: Is there a convincing and well thought-through strategy for commercialization, including regulatory approvals/compliance needed, time to market/deployment, and business and revenue model? Are the key partners identified and committed?

Scale up potential: Does the innovation have the potential to scaleup the company? ***For grant only support,*** *can the applicant demonstrate access to the resources needed to commercialize and scale-up the innovation.*

Broader impact: Will the innovation, if successfully commercialized achieve positive broader societal, economic, environmental, or climate impacts, and ***for Challenge Calls,*** *does it have the potential to contribute to the expected outcomes and impacts set out in the Challenge*?

EIC Accelerator Full Proposal Remote/Interview Evaluation Criteria

Level of risk, implementation, and need for Union support (3/3)

Team: Does the team have the capability and motivation to implement the innovation proposal and bring it to the market? Is there a plan to acquire any critical competencies which are currently missing, including adequate representation of women and men?

Risk level of the investment (for applicants requesting an investment component): Does the nature and level of risk of the investment in your innovation mean that European market actors are unwilling to commit the full amount that is needed without an investment from the EIC Fund? Is there evidence that market actors would be willing to invest, either alongside the EIC or at a later stage?

Risk mitigation: Have the main risks (e.g., tech, market, financial, regulatory) been identified, together with measures to take to mitigate them?

Implementation plan: Is there a clear implementation plan with defined milestones, work packages, and deliverables, together with realistic resources and timings?

EIC Accelerator Submission and Funding Statistics



Project info of the winners are available on [EIC Accelerator data hub]

What Winners Do Differently

A Quick Review of Selected Winning Projects

SMART FARM ROBOTIX

A cost-effective, reliable and fully automated weeding solution

Our robot spares farmers the troubles of manual weeding, eliminates the reliance on expensive and polluting herbicides, and reduces the need for machine weeding.

We use Artificial Intelligence image recognition to spot the weeds among desired plants and utilize smart sensors to provide our robot with self-navigation in and around the field.



We are constantly looking for new passionate colleagues who eager to join our transformative journey

CURRENT OPENINGS

Partners who already trust us

omegga

Solving an ethical dilemma in the egg industry

Supported by

Bundesministerium für Wirtschaft und Klimaschutz

Bundesministerium für Bildung und Forschung

eXIST Existenzgründungen aus der Wissenschaft

eit Food Co-funded by the European Union

Seedbed Incubator

STRASCHEG CENTER FOR ENTREPRENEURSHIP

HM Hochschule München University of Applied Sciences

Member of the Start UP League

STARTUP CERTIFICATE

Forum Moderne Landwirtschaft

The Problem

Annually 7 billion male day-old chicks are killed globally by suffocation with carbon dioxide or "homogenization" through shredding because they neither lay eggs nor produce enough meat to be profitable for the poultry industry.

In 2022, chick killing after hatching was banned by law in Germany and will be in France. Other European countries are following this trend. Starting from 2024, in-ovo sexing technologies after the 7th day of incubation (onset of pain sensation) will be prohibited in Germany.

The only other alternative for culling day-old male chicks is the costly rearing of male layer chicks that require three times the resources compared to specialized broiler breeds and do not find a market due to their low meat yield and tough meat consistency. Therefore, the end consumer, legislator and industry are pushing for a sex classification of unhatched chicks before the development of pain sensation, which is not yet available.

Our Solution

Omegga solves this problem, by developing a continuous, non-invasive measurement technology built into the existing incubation infrastructure of hatcheries to track small sex-specific development differences during the first 6 days of incubation. Repeated measurements of the same egg over time help to compensate for the strong biological variances and to achieve a more accurate classification due to the significantly larger amount of information per egg. The collected data from all 6 days and all sensors are fed into a neural ensemble model, which consists of classification algorithms each optimized on one sex-specific feature.

Male and unfertilized eggs can be sorted out intact, latest on day 6, increasing efficiency by freeing up space for incubation of female eggs and can be used for a variety of other purposes, such as vaccine and feed production, transforming the “lost-opportunity costs” into new revenue streams.

We build and deliver quantum computers for the world

IQM Radiance
for research labs and hpc quantum accelerators

IQM Spark
for research and education

Partners and customers

VTT · IPZ · BLUEFORS · EVIDEN · T-Systems · NVIDIA · SIEMENS · EDF · DLR · esa · Fraunhofer · National Quantum Office Singapore · TII Technology Innovation Institute · Tech Mahindra · Beyond Limits · NORMA · Berkeley · Hebrew University of Jerusalem

Our investors

Vito Ventures · Matadero QED · TESI · MIG Fonds · Santo Venture Capital · OpenOcean · SALVIA · Tofino · Tencent 腾讯 · vsquared ventures · MAKI.VC · European Innovation Council · Bayern Kapital · OurCrowd · WORLDFUND · QCI SPV · VARMA

Objectives

Using quantum computing technologies for the well-being of humankind and creating a safer world for our future generations

Retaining technology sovereignty and establishing Europe as a technology leader to create a secure future

Creating future jobs by commercializing quantum hardware and software

Reskilling the workforce with industrial trainings, educational programs and development initiatives

Creating networks of decision makers, public policy makers and universities to put quantum computing on the European agenda

300+ Colleagues	48+ Nationalities	5 Locations
700+ Publications	200M€+ Funding	2018 Founded

Why now?

01.

Europe, with more than 4.000 Universities, provides most of the physics talents working abroad, causing a brain drain phenomenon.

02.

IQM already has offices in Espoo, Finland; Munich, Germany; Madrid, Spain; and Paris, France, and intends to accelerate its global growth.

03.

Extraordinary progress in scaling quantum computers globally

04.

Quantum computing will be here sooner than expected.

05.

IQM is the Pan-European category leader in building full-stack quantum computers with its own fabrication facility, design, software and one of the largest quantum engineering teams in the world.



Rocksolid AR
Complete software and toolchain solution built for creation of automotive AR applications.

Basemark Automotive Test Suite (BATS)
Graphics and ADAS performance evaluation tool for evaluating automotive SoC.

Basemark Professional Services
Professional services for Automotive OEMs and Tier1-suppliers for support in AR, ADAS, and HMI development.

GPU benchmarks
Graphics performance benchmarks and testing suites for consumer devices.

THE PATH TOWARDS SUSTAINABILITY

Basemark supports the development of sustainable vehicles by developing efficient and innovative automotive software solutions. Basemark's software solutions enable:

- Reduction Of Vehicle Power Consumption By Making More Efficient Use Of Chips
  - Reduction Of Vehicles Needed By Accelerating The Path To Autonomous Vehicles
    - Reduction Of Road Accidents And Fatalities With Autonomous Drive And ADAS
      - Reduction Of The Number Of Chips Needed In Vehicles

VEXLUM

VECSELS

Vertical-External-Cavity Surface-Emitting Lasers for high-impact applications in Quantum Technology, Medicine and Industry.

Vexlum is a spin-off from the Optoelectronics Research Centre (ORC), Tampere University of Technology.

The team has been a leading research group in the area of VECSEL technology for more than a decade. In particular, we have focused on developments concerning optoelectronics materials enabling VECSELs at new wavelengths, scalable manufacturing processes, and application specific systems engineering.

Recent breakthroughs include the use of VECSELs for quantum technology applications.

We capitalize on a comprehensive knowledge in epitaxy, optoelectronics processes, and laser systems. The technical expertise is complemented by proven entrepreneurial skills.

Our vision is to bring VECSEL technology to high impact applications where we can deliver unique benefits in performance, cost, and usability.

Recent News

Press release: Vexlum Was Awarded 2.4M€ Highly Competed EIC Accelerator Grant for Laser Technology Developments
05.03.2024

Exhibiting at APS March Meeting 2024
04.03.2024

Exhibiting at Photonics West 2024
30.01.2024

Season's Greetings and Best Wishes for 2024!
21.12.2023

Greetings from the European Quantum Technologies Conference 2023 EQTC in Hannover!
19.10.2023

Philip Makotyn appointed as the President of Vexlum US
27.09.2023

Exhibiting at ECTI and Quantum World Congress
25.09.2023

ESA – 6th Quantum Technology Conference
19.09.2023

Vexlum is entrepreneur of the year 2023 in Tampere, Finland
05.09.2023

Quantum Flagship project PASQuanS2
01.08.2023

Unveiling biomarker functions in pathology samples

Our bioimaging technology, QF-Pro®, precisely quantifies protein post-translational modifications and protein-protein interactions within single cells and patient pathology samples

Click here to try **QF-Pro®**

QF-Pro® may significantly boost immunotherapy response rates in lung cancer

Partnerships

Industrial CDx Partnerships

In addition to those assays in our portfolio (see Our Assays, to find out more) we also offer custom assay creation to report on specific PPI or PTM targets of your interest. We understand the obstacles that can hinder the creation of new assays, which is why our validated **QF-Pro®** technology presents a perfect way to answer novel scientific questions, providing research and translational medicine teams with the power of functional, quantifiable biomarkers for supporting the development of new drug targets and treatments.

We offer **QF-Pro®** products and assays as companion diagnostic tools for the lifetime of a drug:

- providing new routes to elucidate biologically relevant biomarkers based on protein function
- for the functional shortlisting of targets and mechanistic observation of the MoA of drugs in tissues and cell lines
- as a patient stratification tool for phase I to phase IV trials and, potentially, for patient stratification in commercial treatments in clinical use.

Research Partnerships

At HAWK Biosystems, we thrive on research partnerships and are constantly seeking to work in tandem with clinicians, researchers and academics alike. We have undertaken multiple partnerships with a range of universities and research organisations across several continents.

Academic Programmes

HAWK Biosystems hosts multiple masters' placements from students from the University of the Basque Country (UPV/EHU), University of Bath, and the University of Bristol. HAWK Biosystems also hosts PhD students from a range of different academic backgrounds.

HAWK Biosystems are constantly striving to inspire, train and promote young scientists in a multidisciplinary manner that spans both academia and industry.



PD-1/PD-L1 interaction state predicts patient response and survival in NSCLC



PD-L1 scores miss 24.5% of patients for 1st line immunotherapy



QF-Pro® predicts treatment response even in patients with PD-L1 TPS <1%

LUXQUANTA

Cryptographic techniques used nowadays are no longer future-proof.

This is because the keys are generated based on complex algorithms that would take too long for traditional computers to break, but it will be **easily hackable** by quantum computers.

Quantum Key Distribution (QKD) can provide long-term and future-proof data protection, also against quantum computers.

Quantum Key Distribution (QKD), also known as **Quantum Cryptography,** exploits quantum mechanical properties to securely generate a shared key between two remote network nodes using an optical fibre or through free space.

LuxQuanta Founders at the Forbes List of Changemakers 2024

08 / 01 / 2024



LuxQuanta Supports Gender Equality in the Field of Quantum Technologies & Science

03 / 09 / 2023

LuxQuanta's CEO shares her advice on SheCanCode interview

16 / 10 / 2023

LUXQUANTA WINS THE EIC ACCELERATOR PROGRAM AND SECURES €2.5M

05 / 03 / 2024

The EIC Accelerator's Most Competitive Call Yet

The EIC Accelerator stands as a renowned program of support for high-risk, high-impact innovations and startups across Europe. Known for its strict and rigorous selection process, LuxQuanta's success underscores the company's exceptional team, groundbreaking technology, and the potential societal and market impact of its quantum cryptography technology.

EIC Accelerator represents a Badge of Excellence

With a dedicated team of 25 within just two and a half years of its inception, LuxQuanta is on an ambitious trajectory to become the leading European QKD manufacturer. Following the remarkable achievement of winning the EIC Accelerator, LuxQuanta is set to forge strategic partnerships and raise awareness about the vulnerabilities in current communications systems.

Millow

MYCELIUM + PLANTS = Millow

Millow's unique **Mycelium-based food production** is an amazingly healthy non-meat alternative. It also integrates perfectly with plant based substrates. The natural commonality between plants and fungi unlocks top-level nutritional profiles. Millow is readily absorbed and processed by the human body because it leverages nature-based processes for food production. The combination of Mycelium plus plants also delivers superior texture and mouth-feel. Millow is tasty, healthy, and enjoyable to eat!

- NOTHING ARTIFICIAL
- NON GMO
- ZERO BINDERS
- PURE WHOLEFOOD
- EASILY DIGESTIBLE
- HIGH PROTEIN
- HIGH FIBRE
- LOW WATER USAGE
- LAND RESPONSIBLE
- CRUELTY FREE

25 YEARS OF RELENTLESS RESEARCH

ELSEVIER

Journal of Cleaner Production
Volume 440, 10 February 2024, 140898

Glocal and ecoethical perceptions of engagement with fungi-based food

Coralie Hellwig [a], Hanieh Moshtaghian [a], Dennis Persson [b], Kim Bolton [a], Kamran Rousta [a], Greta Häggblom-Kronlöf [c]

"This study isn't just about fungi-based food; it's a deeper exploration of how our food choices can align with our values"

POWERFUL MEDICAL

PMcardio



Reliable ECG interpretation using AI

PMcardio delivers accurate diagnosis of 39 cardiovascular diseases from any 12-lead ECG in under 5 seconds.

Personalized treatment recommendations for your patients

Reduce the number of unnecessary referrals with individualized treatment recommendations, aligned with the latest clinical guidelines.

PMcardio MODULES

Register to try out PMcardio for free!

PMcardio App

Digitization, diagnostics and treatment recommendation for your patients in one place.

39 diagnoses

Identify heart blocks, arrhythmias and infarctions, as part of 39 diagnoses, from a single ECG.

Clinical validations

PMcardio models have been validated across diverse international patient cohorts.

Certifications

Thanks to our system-wide compliance, PMcardio successfully attained third-party certifications.

945 564	21	32
ECGs scanned	Publications & Abstracts	Global sites in pilot

LUMOVIEW
Building Analytics

Automated Building Models for Energetic Analysis: Using U-Value Measurements and Automated Integration

Discover the fastest way to digitize your Building and reduce CO2 footprint

Get offer



NOVELRAD

Transcatheter Continuous Sutures

Novelrad has developed a micro sewing machine that can deploy a range of continuous suture patterns, percutaneously, with a simple click of a button.

The versatile suturing platform mimics the surgical 'gold standard' and can address multiple indications in the cardiovascular system and beyond.

Minimally invasive suturing for vascular and heart defect closure

Our solution for large bore vascular closure

A percutaneous suturing device for closing vascular access sites following catheterization procedures.

The device deploys a multipoint purse string suture at the beginning of the procedure, thereby, enabling safe dilation and reliable closure at the end of the procedure.

The Novelrad VCD features an unprecedented range of bore sizes using a single device



BetaGlue TECHNOLOGIES

an innovative approach in the fight against cancer

Localized Internal β-emitting Radiotherapy

A new anti-tumoral compound based on ^{90}Y β-emitting microspheres, embedded in a glue matrix and delivered to target with a dedicated delivery system.

The amount of energy needed is administered locally with a simple, intra-operative method.

BetaGlue has closed a 10 million euro equity financing round

28/07/2022

BetaGlue Technologies **has closed a EUR 10 million equity financing round : Fin Posillipo** (Petrone Group), **Kairos Partners SGR**, **LIFTT** (Venture Capital led by Stefano Buono, founder of AAA), **Neva Sgr** (Intesa Sanpaolo Group), **Profequycapital** and **Romed** will be joining the company's capital , with a reinvestment from existing investors **Innogest Capital** and **Panakès Partners** .

BetaGlue has enrolled the first patient treated with BAT-90 in its First-in-Human trials, taking radiotherapy inside solid tumours

27/07/2022

BetaGlue Technologies **has enrolled the first patient in a clinical trial** with**BAT-90** , the company's cancer radiotherapy platform. The first clinical findings have shown thatBAT-90 makes it possible to treat only the area where the tumour is located, while avoiding the surroundingtissues, so as to combine treatment efficacy and patient safety.

The **clinical trial** in **liver cancer** patient has been coordinated by **Professor MalkhazMizandari** at the **New Hospitals in Tbilisi** (Georgia), an international centre of excellenceaffiliated with Thomas Jefferson University in Philadelphia (USA).

Thank you! Best wishes!
Any comments or questions?



[Türkiye in Horizon 2020/Europe web site]



[Help Desk] [X (Twitter)] [LinkedIn] [YouTube] [info@TurkeyinH2020.eu]